FTY720-Mitoxy reduces synucleinopathy and neuroinflammation, restores behavior and mitochondria function, and increases GDNF expression in Multiple System Atrophy mouse models

[1]  J. B. Arterburn,et al.  FTY720-Mitoxy reduces toxicity associated with MSA-like α-synuclein and oxidative stress by increasing trophic factor expression and myelin protein in OLN-93 oligodendroglia cell cultures , 2019, Neuropharmacology.

[2]  N. Lazar,et al.  Moving to a World Beyond “p < 0.05” , 2019, The American Statistician.

[3]  Alejandro F Frangi,et al.  Iba-1-/CD68+ microglia are a prominent feature of age-associated deep subcortical white matter lesions , 2019, PloS one.

[4]  Javier Vargas-Medrano,et al.  Up-regulation of protective neuronal MicroRNAs by FTY720 and novel FTY720-derivatives , 2019, Neuroscience Letters.

[5]  R. Gottlieb,et al.  Oxidative muscles have better mitochondrial homeostasis than glycolytic muscles throughout life and maintain mitochondrial function during aging , 2018, Aging.

[6]  S. Salani,et al.  Mitochondrial Dysregulation and Impaired Autophagy in iPSC-Derived Dopaminergic Neurons of Multiple System Atrophy , 2018, Stem cell reports.

[7]  L. Giono,et al.  Target RNAs Strike Back on MicroRNAs , 2018, Front. Genet..

[8]  S. Taheri,et al.  The Effect of Diet on Improved Endurance in Male C57BL/6 Mice , 2018, Nutrients.

[9]  C. Strand,et al.  Immunohistochemical and Molecular Investigations Show Alteration in the Inflammatory Profile of Multiple System Atrophy Brain , 2018, Journal of neuropathology and experimental neurology.

[10]  D. Gomez-Nicola,et al.  Neuroinflammation: Microglia and T Cells Get Ready to Tango , 2018, Front. Immunol..

[11]  W. Poewe,et al.  Progressive striatonigral degeneration in a transgenic mouse model of multiple system atrophy: translational implications for interventional therapies , 2018, Acta Neuropathologica Communications.

[12]  J. Joseph,et al.  Mitochondria-Targeted Triphenylphosphonium-Based Compounds: Syntheses, Mechanisms of Action, and Therapeutic and Diagnostic Applications. , 2017, Chemical reviews.

[13]  W. D. den Dunnen,et al.  Increased White Matter Inflammation in Aging- and Alzheimer’s Disease Brain , 2017, Front. Mol. Neurosci..

[14]  Javier Vargas-Medrano,et al.  FTY720 (Fingolimod) reverses α-synuclein-induced downregulation of brain-derived neurotrophic factor mRNA in OLN-93 oligodendroglial cells , 2017, Neuropharmacology.

[15]  E. Benarroch,et al.  Anhidrosis in multiple system atrophy involves pre‐ and postganglionic sudomotor dysfunction , 2017, Movement disorders : official journal of the Movement Disorder Society.

[16]  Javier Vargas-Medrano,et al.  FTY720-derivatives do not induce FTY720-like lymphopenia , 2017, Journal of pharmacological sciences.

[17]  Y. Yoshida,et al.  The Effects of Aging and Treadmill Running on Soleus and Gastrocnemius Muscle Morphology in the Senescence-Accelerated Mouse ( SAMP 1 ) , 2017 .

[18]  E. Masliah,et al.  Multiple system atrophy: experimental models and reality , 2017, Acta Neuropathologica.

[19]  Xinbing Wei,et al.  FTY720 Attenuates 6-OHDA-Associated Dopaminergic Degeneration in Cellular and Mouse Parkinsonian Models , 2017, Neurochemical Research.

[20]  C. Kleinschnitz,et al.  Fingolimod (FTY720) Reduces Cortical Infarction and Neurological Deficits During Ischemic Stroke Through Potential Maintenance of Microvascular Patency. , 2016, Current neurovascular research.

[21]  A. Watanyar,et al.  Preclinical Metabolism, Pharmacokinetics and In Vivo Analysis of New Blood-Brain-Barrier Penetrant Fingolimod Analogues: FTY720-C2 and FTY720-Mitoxy , 2016, PloS one.

[22]  Javier Vargas-Medrano,et al.  FTY720/Fingolimod Reduces Synucleinopathy and Improves Gut Motility in A53T Mice , 2016, The Journal of Biological Chemistry.

[23]  P. Popoli,et al.  Fingolimod: A Disease-Modifier Drug in a Mouse Model of Amyotrophic Lateral Sclerosis , 2016, Neurotherapeutics.

[24]  K. Jellinger.  Recent advances in multiple system atrophy , 2016 .

[25]  I. Kleiter,et al.  Fingolimod for multiple sclerosis and emerging indications: appropriate patient selection, safety precautions, and special considerations , 2016, Therapeutics and clinical risk management.

[26]  G. Wenning,et al.  Review: Multiple system atrophy: emerging targets for interventional therapies , 2016, Neuropathology and applied neurobiology.

[27]  H. Al-Hindi,et al.  Large‐scale mitochondrial DNA deletion underlying familial multiple system atrophy of the cerebellar subtype , 2015, Clinical case reports.

[28]  I. Strömberg,et al.  GDNF Overexpression from the Native Locus Reveals its Role in the Nigrostriatal Dopaminergic System Function , 2015, PLoS genetics.

[29]  A. Margioris,et al.  Fingolimod induces neurogenesis in adult mouse hippocampus and improves contextual fear memory , 2015, Translational Psychiatry.

[30]  W. Poewe,et al.  Involvement of Peripheral Nerves in the Transgenic PLP-α-Syn Model of Multiple System Atrophy: Extending the Phenotype , 2015, PloS one.

[31]  C. Trebst,et al.  Effect of FTY720-phosphate on the expression of inflammation-associated molecules in astrocytes in vitro. , 2015, Molecular medicine reports.

[32]  H. Hartung,et al.  Fingolimod induces the transition to a nerve regeneration promoting Schwann cell phenotype , 2015, Experimental Neurology.

[33]  Stephanie L. Alberico,et al.  The Vulnerable Ventral Tegmental Area in Parkinson's Disease. , 2015, Basal ganglia.

[34]  A. Giralt,et al.  Fingolimod (FTY720) enhances hippocampal synaptic plasticity and memory in Huntington's disease by preventing p75NTR up-regulation and astrocyte-mediated inflammation. , 2015, Human molecular genetics.

[35]  Filamentous aggregations of phosphorylated α-synuclein in Schwann cells (Schwann cell cytoplasmic inclusions) in multiple system atrophy , 2015, Acta neuropathologica communications.

[36]  G. Wenning,et al.  Multiple-system atrophy. , 2015, The New England journal of medicine.

[37]  K. Jellinger.  Neuropathology of multiple system atrophy: New thoughts about pathogenesis , 2014, Movement disorders : official journal of the Movement Disorder Society.

[38]  E. Masliah,et al.  α-Synuclein impairs oligodendrocyte progenitor maturation in multiple system atrophy , 2014, Neurobiology of Aging.

[39]  H. Mizoguchi,et al.  Fingolimod increases brain-derived neurotrophic factor levels and ameliorates amyloid β-induced memory impairment , 2014, Behavioural Brain Research.

[40]  J. B. Arterburn,et al.  Novel FTY720-Based Compounds Stimulate Neurotrophin Expression and Phosphatase Activity in Dopaminergic Cells. , 2014, ACS medicinal chemistry letters.

[41]  Cheng Luo,et al.  Active, phosphorylated fingolimod inhibits histone deacetylases and facilitates fear extinction memory , 2014, Nature Neuroscience.

[42]  E. Amico,et al.  FTY720 (fingolimod) is a neuroprotective and disease-modifying agent in cellular and mouse models of Huntington disease. , 2014, Human molecular genetics.

[43]  Wei Tang,et al.  Potential Therapeutic Effects of Neurotrophins for Acute and Chronic Neurological Diseases , 2014, BioMed research international.

[44]  D. Galasko,et al.  Widespread microRNA dysregulation in multiple system atrophy – disease‐related alteration in miR‐96 , 2014, The European journal of neuroscience.

[45]  G. Wenning,et al.  Animal models of multiple system atrophy , 2005, Clinical Autonomic Research.

[46]  Jun Chen,et al.  Age-related decline of myelin proteins is highly correlated with activation of astrocytes and microglia in the rat CNS. , 2013, International journal of molecular medicine.

[47]  T. Révész,et al.  Identification and Quantification of Oligodendrocyte Precursor Cells in Multiple System Atrophy, Progressive Supranuclear Palsy and Parkinson's Disease , 2013, Brain pathology.

[48]  Shijie Jin,et al.  Fingolimod Phosphate Attenuates Oligomeric Amyloid β–Induced Neurotoxicity via Increased Brain-Derived Neurotrophic Factor Expression in Neurons , 2013, PloS one.

[49]  A. Suzumura,et al.  Fingolimod phosphate promotes the neuroprotective effects of microglia , 2013, Journal of Neuroimmunology.

[50]  K. Vogt,et al.  Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome , 2012, Proceedings of the National Academy of Sciences.

[51]  A. Singleton,et al.  Lewy-like aggregation of α-synuclein reduces protein phosphatase 2A activity in vitro and in vivo , 2012, Neuroscience.

[52]  J. Winkler,et al.  Fluoxetine ameliorates behavioral and neuropathological deficits in a transgenic model mouse of α-synucleinopathy , 2012, Experimental Neurology.

[53]  E. Tolosa,et al.  Premotor signs and symptoms of multiple system atrophy , 2012, The Lancet Neurology.

[54]  Patrick S. Aranda,et al.  Bleach gel: A simple agarose gel for analyzing RNA quality , 2012, Electrophoresis.

[55]  E. Masliah,et al.  Multiple system atrophy: a clinical and neuropathological perspective , 2011, Trends in Neurosciences.

[56]  A. Toga,et al.  Callosal tissue loss in multiple system atrophy—A one‐year follow‐up study , 2010, Movement disorders : official journal of the Movement Disorder Society.

[57]  A. Sidhu,et al.  Mice expressing the A53T mutant form of human alpha‐synuclein exhibit hyperactivity and reduced anxiety‐like behavior , 2010, Journal of neuroscience research.

[58]  E. Masliah,et al.  Neurodegeneration in a Transgenic Mouse Model of Multiple System Atrophy Is Associated with Altered Expression of Oligodendroglial-Derived Neurotrophic Factors , 2010, The Journal of Neuroscience.

[59]  D. D. Di Monte,et al.  Serine 129 Phosphorylation Reduces the Ability of α-Synuclein to Regulate Tyrosine Hydroxylase and Protein Phosphatase 2A in Vitro and in Vivo , 2010, The Journal of Biological Chemistry.

[60]  T. Nayak,et al.  Synthesis and characterization of iodinated tetrahydroquinolines targeting the G protein-coupled estrogen receptor GPR30. , 2010, Journal of medicinal chemistry.

[61]  V. Brinkmann.  FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system , 2009, British journal of pharmacology.

[62]  E. Masliah,et al.  Mitochondrial inhibitor 3‐nitroproprionic acid enhances oxidative modification of alpha‐synuclein in a transgenic mouse model of multiple system atrophy , 2009, Journal of neuroscience research.

[63]  Sid Gilman,et al.  Prospective differentiation of multiple system atrophy from Parkinson disease, with and without autonomic failure. , 2009, Archives of neurology.

[64]  M. Graeber,et al.  Microglia: biology and pathology , 2009, Acta Neuropathologica.

[65]  E. Waxman,et al.  Specificity and Regulation of Casein Kinase-Mediated Phosphorylation of &agr;-Synuclein , 2008, Journal of neuropathology and experimental neurology.

[66]  W. Poewe,et al.  Microglial activation mediates neurodegeneration related to oligodendroglial α‐synucleinopathy: Implications for multiple system atrophy , 2007, Movement disorders : official journal of the Movement Disorder Society.

[67]  B. Bloem,et al.  Too hot to handle: heat stroke in multiple system atrophy , 2007, Journal of Neurology.

[68]  M. Straume,et al.  Transient T cell accumulation in lymph nodes and sustained lymphopenia in mice treated with FTY720 , 2005, European journal of immunology.

[69]  Makoto Hashimoto,et al.  Neurological and Neurodegenerative Alterations in a Transgenic Mouse Model Expressing Human α-Synuclein under Oligodendrocyte Promoter: Implications for Multiple System Atrophy , 2005, The Journal of Neuroscience.

[70]  Klaus Seppi,et al.  Grading of neuropathology in multiple system atrophy: Proposal for a novel scale , 2005, Movement disorders : official journal of the Movement Disorder Society.

[71]  L. Stefanis,et al.  α-Synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells , 2005, Journal of Cell Science.

[72]  J. Trojanowski,et al.  Mouse Model of Multiple System Atrophy α-Synuclein Expression in Oligodendrocytes Causes Glial and Neuronal Degeneration , 2005, Neuron.

[73]  Werner Poewe,et al.  Oxidative stress in transgenic mice with oligodendroglial alpha-synuclein overexpression replicates the characteristic neuropathology of multiple system atrophy. , 2005, The American journal of pathology.

[74]  A. Takahashi,et al.  The assessment of sudomotor dysfunction in multiple system atrophy , 1991, Clinical Autonomic Research.

[75]  Tomohiro Yoshida.  Immunohistochemical localization of glial cell line-derived neurotrophic factor and its receptor Ret in the rat sweat gland. , 2004, The Kurume medical journal.

[76]  Y. Yoshida,et al.  The effects of aging and treadmill running on soleus and gastrocnemius muscle morphology in the senescence-accelerated mouse (SAMP1). , 2004, The journals of gerontology. Series A, Biological sciences and medical sciences.

[77]  David W. Miller,et al.  Glial cell inclusions and the pathogenesis of neurodegenerative diseases. , 2004, Neuron glia biology.

[78]  M. Eccles,et al.  Delivery of antisense peptide nucleic acids (PNAs) to the cytosol by disulphide conjugation to a lipophilic cation , 2004, FEBS letters.

[79]  T. Mizutani,et al.  Microglial Activation Parallels System Degeneration in Multiple System Atrophy , 2004, Journal of neuropathology and experimental neurology.

[80]  S. Payne,et al.  The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2 , 2003, FEBS letters.

[81]  M. Zigmond,et al.  Can the brain be protected through exercise? Lessons from an animal model of parkinsonism☆ , 2003, Experimental Neurology.

[82]  K. Jellinger,et al.  Neuropathological and behavioral changes induced by various treatment paradigms with MPTP and 3-nitropropionic acid in mice: towards a model of striatonigral degeneration (multiple system atrophy) , 2003, Acta Neuropathologica.

[83]  J. Trojanowski,et al.  Initiation and Synergistic Fibrillization of Tau and Alpha-Synuclein , 2003, Science.

[84]  M. Zigmond,et al.  Neuroprotective effects of prior limb use in 6‐hydroxydopamine‐treated rats: possible role of GDNF , 2003, Journal of neurochemistry.

[85]  D. Wright,et al.  Restorative effects of neurotrophin treatment on diabetes-induced cutaneous axon loss in mice , 2003, Experimental Neurology.

[86]  Hideo Fujiwara,et al.  Hyperphosphorylation and insolubility of α‐synuclein in transgenic mouse oligodendrocytes , 2002 .

[87]  C. Cotman,et al.  Exercise: a behavioral intervention to enhance brain health and plasticity , 2002, Trends in Neurosciences.

[88]  J. Trojanowski,et al.  Neuronal α-Synucleinopathy with Severe Movement Disorder in Mice Expressing A53T Human α-Synuclein , 2002, Neuron.

[89]  G. Horgan,et al.  Relative expression software tool (REST©) for group-wise comparison and statistical analysis of relative expression results in real-time PCR , 2002 .

[90]  J. Trojanowski,et al.  Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. , 2002, Neuron.

[91]  A. Scallet,et al.  Biomarkers of 3‐Nitropropionic Acid (3‐NPA)‐Induced Mitochondrial Dysfunction as Indicators of Neuroprotection , 2001, Annals of the New York Academy of Sciences.

[92]  H U Rehman,et al.  Multiple system atrophy , 2001, Postgraduate medical journal.

[93]  I. Akiguchi,et al.  Glial cell line-derived neurotrophic factor-like immunoreactivity in the cerebella of normal subjects and patients with multiple system atrophy , 2000, Acta Neuropathologica.

[94]  D. Dickson,et al.  Multiple System Atrophy: A Sporadic Synucleinopathy , 1999, Brain pathology.

[95]  J. Kimura,et al.  Increased brain-derived neurotrophic factor-containing axons in the basal ganglia of patients with multiple system atrophy. , 1999, Journal of neuropathology and experimental neurology.

[96]  Y. Yanagawa,et al.  FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats, III. Increase in frequency of CD62L‐positive T cells in Peyer’s patches by FTY720‐induced lymphocyte homing , 1998, Immunology.

[97]  Hitoshi Takahashi,et al.  Accumulation of α-synuclein/NACP is a cytopathological feature common to Lewy body disease and multiple system atrophy , 1998, Acta Neuropathologica.

[98]  H. Kataoka,et al.  FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. , 1998, Journal of immunology.

[99]  A. Kakita,et al.  Accumulation of alpha-synuclein/NACP is a cytopathological feature common to Lewy body disease and multiple system atrophy. , 1998, Acta neuropathologica.

[100]  S. Landis,et al.  The Role of Acetylcholine in Regulating Secretory Responsiveness in Rat Sweat Glands , 1995, Molecular and Cellular Neuroscience.

[101]  O. Blin,et al.  Mitochondrial respiratory failure in skeletal muscle from patients with Parkinson's disease and multiple system atrophy , 1994, Journal of the Neurological Sciences.

[102]  Peter L. Lantos,et al.  Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome) , 1989, Journal of the Neurological Sciences.

[103]  S. Landis,et al.  Neonatal treatment with nerve growth factor antiserum eliminates cholinergic sympathetic innervation of rat sweat glands. , 1985, Developmental biology.

[104]  P. K. Smith,et al.  Measurement of protein using bicinchoninic acid. , 1985, Analytical biochemistry.

[105]  北村 聖.  "The New England Journal of Medicine". , 1962, British medical journal.